Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

About this update from Milestone Pharmaceuticals Inc.

MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences. To request a 1x1 meeting, please contact your representative at the relevant bank. Webcasts of the presentations will be available for approximately 90 days following each event on the "News & Events" section of Milestone's website www.milestonepharma.com. About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone's lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/ Contact: Investor Relations Kevin Gardner, [email protected] Media Relations   Rebecca Novak, [email protected]

View stock analysis, news, and events for Milestone Pharmaceuticals Inc.